Pair Name | Ilexgenin A, Sorafenib | ||
Phytochemical Name | Ilexgenin A (PubChem CID: 21672638 ) | ||
Anticancer drug Name | Sorafenib (PubChem CID: 216239 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Drug Name | Sorafenib |
Adverse Reactions | Facial red macules, dry skin, acne, alveolitis. This was inferred hot nature anticancer drug. |
Recommendations | Cold: Ilex hainanensis; Mangifera indica; Camellia sinensis; Sophora flavescens; Eriobotrya japonica; Citrus aurantium; |
Reference | Malignant tumors in the era of immunotherapy based on traditional Chinese medicine's "cold and hot theory" Construction of integrated traditional Chinese and Western medicine treatment paradigm[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine,2023,32(12):1712-1716. DOI:10.3969/j.issn.1008-8849.2023.12.022. ref_link |
Pair Name | Ilexgenin A, Sorafenib | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Inhibition-->Angiogenesis | |||
Gene Regulation | Up-regulation | Expression | CASP3 | hsa836 |
Up-regulation | Expression | CASP7 | hsa840 | |
Down-regulation | Expression | IL6 | hsa3569 | |
Down-regulation | Expression | MVD | hsa4597 | |
Down-regulation | Expression | PIK3CA | hsa5290 | |
Down-regulation | Expression | STAT3 | hsa6774 | |
Down-regulation | Expression | TNF | hsa7124 | |
Down-regulation | Expression | VEGFA | hsa7422 | |
In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
Result | The results described in the present study identifies Ilexgenin A as a promising therapeutic candidate that modulates inflammation, angiogenesis, and HCC growth. |
No. | Title | Href |
---|---|---|
1 | Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth. Toxicol Appl Pharmacol. 2017 Jan 15;315:90-101. doi: 10.1016/j.taap.2016.12.008. | Click |